Abstract
It has been brought to our attention that the affiliation of Dr. Jerzy Pieczykolan at the time when he was responsible for the work described in the paper [...].
Highlights
M. et al A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells
It has been brought to our attention that the affiliation of Dr Jerzy Pieczykolan at the time when he was responsible for the work described in the paper [1] was not mentioned in the previous published version
Add the following affiliation as the current address of Dr Jerzy Pieczykolan: Preclinical Development Department, R&D Celon Pharma Inc., 05-092 Lomianki/Kielpin, Poland; jerzy.pieczykolan@celonpharma.com. This correction does not cause any changes to results and conclusions in the original published paper
Summary
M. et al A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Sochaj-Gregorczyk 1, Jerzy Pieczykolan 2,† , Daniel Krowarsch 3 , Filip Jelen 4 and Jacek Otlewski 1,* Department of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, 50-137 Wroclaw, Poland; aniaserwotka@wp.pl (A.M.S.-S.); alicja.sochaj-gregorczyk@uj.edu.pl (A.M.S.-G.)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.